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Although the pathogenesis of rheumatoid arthritis (RA)
remains unclear, multiple exogenous and endogenous
antigenic triggers, in the presence of a genetic
predisposition, initiate many autoimmune responses in the
synovial compartment. Many cell populations, including
monocytes, macrophages, B cells, T cells, endothelial cells,
and fibroblasts, contribute to the inflammatory process. In RA,
B lymphocytes have been implicated in the pathogenesis of
rheumatoid synovitis.
The precise role played by B cells in RA is not fully
understood, but potential mechanisms include an antigen-
presenting function, secretion of proinflammatory cytokines,
production of rheumatoid factor, and co-stimulation of T cells.
The chimeric monoclonal antibody rituximab, which targets
the CD20 antigen on B lymphocytes, has been used
extensively in the treatment of B cell malignancies. More than
300,000 patients with non-Hodgkin’s lymphoma, chronic
lymphocytic leukemia, and other B cell diseases have been
treated with rituximab, and more recently the agent has
emerged as a potential treatment for RA via selective B
lymphocyte depletion.
Clinical experience in the oncology setting shows that
rituximab is well tolerated, with mild-to-moderate infusion
reactions – most often during the first infusion phase – being
the most common adverse event. Rare serious adverse
events do occur but, because they are often related to
circulating tumor loads or to the disease itself, it can be
expected that these events will arise to a lesser extent with
RA.
B cell targeted therapies represent an innovative approach to
the treatment of RA. Ongoing research continues to evaluate
the critical roles of B cells in sustaining the chronic
inflammatory process of RA. These findings have contributed
to the development of other targeted therapies that delete B
cells, such as belimumab, an inhibitor of B lymphocyte
stimulation. In a phase I trial belimumab treatment significantly
reduced CD20+ levels in patients with systemic lupus
erythematosus.
The ultimate therapeutic goal in the treatment of any disease
is a cure. Until the pathophysiology/etiology of RA is better
understood, treatment strategies must focus on disease
management. Early diagnosis and treatment with disease-
modifying antirheumatic drugs (DMARDs) are necessary to
reduce early joint damage, functional loss, and mortality.
However, choosing which patients should receive
combination DMARDs, and which combinations, remains one
of our major challenges in treating RA patients.
Many well controlled clinical trials demonstrate that
methotrexate and other DMARDs, including the tumor
necrosis factor-α inhibitors, have shown considerable efficacy
in controlling the inflammatory process, but many patients
continue to have active disease. Optimizing clinical response
requires the use of a full spectrum of clinical agents with
different therapeutic targets. Newer therapies, such as
rituximab, that specifically target B cells have emerged as
viable treatment options for patients with RA.
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